TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30280443

Group type: EXPERIMENTAL
Intervention: Early stressful life events and negative parent-child interaction assessed at ages 2-5
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Low levels of inhibitory control
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Late childhood problem behavior
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Parental drug use
Number of subjects: 364
Study: 30227941

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 26387692

Group type: EXPERIMENTAL
Intervention: Modified protocol (2 mg per kg body weight given in a single infusion over 2 h, repeated every 4 months)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard protocol (1 mg per kg body weight over 4 h on 3 successive days, repeated every 4 months)
Number of subjects: 18
Study: 25249305

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 22456026

Group type: EXPERIMENTAL
Intervention: FD‐OCT guidance
Number of subjects: 70

Group type: COMPARATOR
Intervention: IVUS guidance
Number of subjects: 70
Study: 20883925

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 2645
Study: 18571082

Group type: EXPERIMENTAL
Intervention: Data-injection ring system
Number of subjects: 96

Group type: COMPARATOR
Intervention: No data-injection system
Number of subjects: 96
Study: 16025732

Group type: EXPERIMENTAL
Intervention: Direct hypnotic procedure using the Harvard Group Scale of Hypnotic Susceptibility: Form A (HGSHS:A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indirect hypnotic procedure using the Alman‐Wexler Indirect Hypnotic Susceptibility Scale (AWIHSS)
Number of subjects: 0
Study: 12064813

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg/day
Number of subjects: 79

Group type: COMPARATOR
Intervention: Rufloxacin 400 mg/week
Number of subjects: 79
Study: 10495686

Group type: EXPERIMENTAL
Intervention: Metoprolol administration at an initial dose of 25 mg/day (12.5 mg for class III-IV patients), increased to a maximum of 200 mg/day
Number of subjects: 3991

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3991
Study: 7588348

Group type: EXPERIMENTAL
Intervention: Histoacryl plus sclerotherapy with polidocanol
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional sclerotherapy with polidocanol alone
Number of subjects: 126
Study: 1773685

Group type: EXPERIMENTAL
Intervention: Decision support system for insulin-dose adjustment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Recommendations from the education team (Control)
Number of subjects: 42
Study: 7065660

Group type: EXPERIMENTAL
Intervention: Topically applied mechlorethamine hydrochloride
Number of subjects: 42

Group type: COMPARATOR
Intervention: Total-skin electron-beam irradiation
Number of subjects: 42
Study: 30639231

Group type: EXPERIMENTAL
Intervention: N. sativa seed oil (2.5 mL every 12 hours for 3 months)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: N. sativa seed oil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 28688693

Group type: EXPERIMENTAL
Intervention: Very Accelerated Radiotherapy (VART): 64.8Gy/3.5 weeks
Number of subjects: 179

Group type: COMPARATOR
Intervention: Conventional CRT: 70Gy/7 weeks + 3 cycles carboplatin-5FU
Number of subjects: 179

Group type: COMPARATOR
Intervention: Moderately accelerated CRT: 70Gy/6 weeks + 2 cycles carboplatin-5FU
Number of subjects: 179

Group type: COMPARATOR
Intervention: Strongly intensified CRT: 64Gy/5 weeks + cisplatin (days 2, 16, 30) and 5 FU (days 1-5, 29-33) followed by 2 cycles adjuvant cisplatin-5FU
Number of subjects: 179
Study: 25855918

Group type: EXPERIMENTAL
Intervention: Low dose of arginine (5.7 g per day)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Medium dose of arginine (12.3 g per day)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: High dose of arginine (18.9 g per day)
Number of subjects: 84
Study: 24622416

Group type: EXPERIMENTAL
Intervention: 6.5 mg/kg ATG over four days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 6.5 mg/kg ATG
Number of subjects: 58
Study: 21878823

Group type: EXPERIMENTAL
Intervention: Plyometric training program for 6 weeks, 3 days per week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study: 18661120

Group type: EXPERIMENTAL
Intervention: eMPC advised insulin infusion
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard care insulin algorithms
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: eMPC advised glucose measurement interval
Number of subjects: 34
Study: 17980184

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 15202162

Group type: EXPERIMENTAL
Intervention: Granisetron (single oral dose)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ondansetron (2 intravenous doses of 0.15 mg/kg followed by 1 oral dose)
Number of subjects: 33
Study: 11911549

Group type: EXPERIMENTAL
Intervention: Levodopa and carbidopa (higher dosages)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Levodopa and carbidopa (lower dosages)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 82
Study: 9832658

Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate tissue adhesive
Number of subjects: 136

Group type: COMPARATOR
Intervention: Monofilament sutures
Number of subjects: 136
Study: 7522132

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cocaine infusion
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cocaine users (baseline)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nonusers (baseline)
Number of subjects: 25
Study: 2563317

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.15 mg.kg‐1
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.15 mg.kg‐1
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 98
Study: 4802598

Group type: EXPERIMENTAL
Intervention: Vaccinated employees in factories
Number of subjects: 51219

Group type: EXPERIMENTAL
Intervention: Vaccinated telecommunications units
Number of subjects: 51219

Group type: COMPARATOR
Intervention: Unvaccinated controls in telecommunications units
Number of subjects: 51219
Study: 31604416

Group type: EXPERIMENTAL
Intervention: General practice-based preventive health checks
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Daily smoking
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: High-risk alcohol consumption
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Poor lung function
Number of subjects: 364
Study: 27749739

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (0.625 mg/d)
Number of subjects: 1616

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1616
Study: 25919636

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 23514773

Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 2341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2341
Study: 21771304

Group type: EXPERIMENTAL
Intervention: Radio Electric Asymmetric Treatment (REAC) using Neuro Psycho Physical Optimization (NPPO) for 4 weeks
Number of subjects: 888

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 888
Study: 19467365

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel 0.025% for 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel 0.05% for 2 or 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle gel for 3 days
Number of subjects: 0
Study: 16323095

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg daily for 7-14 days)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Levofloxacin (500 mg daily for 7-14 days)
Number of subjects: 394
Study: 14982609

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 73

Group type: COMPARATOR
Intervention: Breath Awareness
Number of subjects: 73
Study: 11467760

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 20
Study: 10190078

Group type: EXPERIMENTAL
Intervention: Intensive course of high fractional X‐ray therapy (cumulative dose up to 25 Gy) with direct protracted endolymphatic chemotherapy with 5‐fluorouracil (5‐FU) instilled in 600 mg/m2 each day before operation, up to a cumulative dose of 5 g.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ukrain as monotherapy, 10 mg each second day before operation (up to a cumulative dose of 60 mg) and a total of 40 mg after surgical intervention, with repeated courses (100 mg/per course) 6 months after surgical operation.
Number of subjects: 48
Study: 8068375

Group type: EXPERIMENTAL
Intervention: Telephone administration of questionnaires to non-respondents
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Postal survey
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Telephone approach
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Postal non-respondents
Number of subjects: 1732
Study: 3395733

Group type: EXPERIMENTAL
Intervention: Exploratory therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prescriptive therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 30509427

Group type: EXPERIMENTAL
Intervention: Arthroscopic technique
Number of subjects: 75

Group type: COMPARATOR
Intervention: Open technique
Number of subjects: 75
Study: 28532387

Group type: EXPERIMENTAL
Intervention: Trastuzumab added to chemotherapy
Number of subjects: 1574

Group type: EXPERIMENTAL
Intervention: Penalized regression models using adaptive lasso
Number of subjects: 1574

Group type: EXPERIMENTAL
Intervention: Double cross-validation
Number of subjects: 1574

Group type: EXPERIMENTAL
Intervention: Prediction model with 4 clinical covariates, 98 biomarkers, and 24 biomarker-by-treatment interactions
Number of subjects: 1574
Study: 26380442

Group type: EXPERIMENTAL
Intervention: Jiangyabao serial drugs combined with Western medicine (WM)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Simulative agents of Jiangyabao serial drugs combined with Western medicine (WM)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Combined hypotensive treatment program with Nifedipine Sustained Release Tablet and Hydrochlorothiazide
Number of subjects: 199
Study: 24432069

Group type: EXPERIMENTAL
Intervention: Swim cast
Number of subjects: 68

Group type: COMPARATOR
Intervention: Traditional cast
Number of subjects: 68
Study: 20333384

Group type: EXPERIMENTAL
Intervention: HA-Irinotecan (HA 1,000 mg/m(2) and irinotecan at 350 mg/m(2))
Number of subjects: 76

Group type: COMPARATOR
Intervention: irinotecan (350 mg/m(2))
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: HA-Irinotecan
Number of subjects: 76

Group type: COMPARATOR
Intervention: irinotecan
Number of subjects: 76
Study: 19060449

Group type: EXPERIMENTAL
Intervention: Pueraria mirifica (PM)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16927582

Group type: EXPERIMENTAL
Intervention: Citalopram adherence intervention with trained care managers
Number of subjects: 228
Study: 12508081

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) and hydrocortisone supplementation (6 micro g.kg(‐1).d(‐1) of T3 with 1 mg.kg(‐1).d(‐1) of hydrocortisone)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: T3 and hydrocortisone supplementation
Number of subjects: 253
Study: 10335931

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg p.o. twice a day
Number of subjects: 173

Group type: COMPARATOR
Intervention: Ceftriaxone 2 g i.v. as a single daily dose
Number of subjects: 173
Study: 8915757

Group type: EXPERIMENTAL
Intervention: Intrathecal rIL-2 immunotherapy (daily administration)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Systemic rIL-2 infusion following intrathecal treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clinical condition post-treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intrathecal rIL-2 treatment side effects
Number of subjects: 8
Study: 12284145

Group type: EXPERIMENTAL
Intervention: Gemeprost 1 mg pessaries
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Prostaglandin E2 10 mg pessaries
Number of subjects: 1030
Study: 387070

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (800 mg sulphamethoxazole and 160 mg trimethoprim) administered as a single 10 ml intravenous infusion during surgery.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo administered as a single 10 ml intravenous infusion during surgery.
Number of subjects: 50
Study: 31147187

Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3)
Number of subjects: 90

Group type: COMPARATOR
Intervention: HeartMate II (HMII)
Number of subjects: 90
Study: 28864487

Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Number of subjects: 69

Group type: COMPARATOR
Intervention: Pap screening (HCP-administered)
Number of subjects: 69
Study: 26291445

Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24122077

Group type: EXPERIMENTAL
Intervention: Entropy measurements using Datex-Ohmeda-M-EntropyTM module
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Standard sedation regimen (propofol and fentanyl)
Number of subjects: 27
Study: 22522428

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (9-month after school program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 19398687

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 800
Study: 17199579

Group type: EXPERIMENTAL
Intervention: Calcitriol ointment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Number of subjects: 5

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 5
Study: 15750763

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 2702

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2702
Study: 11939866

Group type: EXPERIMENTAL
Intervention: H perforatum (St John's wort)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 9790546

Group type: EXPERIMENTAL
Intervention: Bilateral orchiectomy plus placebo
Number of subjects: 739

Group type: COMPARATOR
Intervention: Bilateral orchiectomy plus flutamide
Number of subjects: 739
Study: 7896149

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day for 3 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 32
Study: 2896826

Group type: EXPERIMENTAL
Intervention: Two-component vaccine containing formaldehyde detoxified lymphocytosis promoting factor (LPF) and filamentous haemagglutinin
Number of subjects: 3801

Group type: EXPERIMENTAL
Intervention: LPF-toxoid vaccine
Number of subjects: 3801

Group type: COMPARATOR
Intervention: Placebo (vaccine solvent)
Number of subjects: 3801
Study: 31937513

Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) 50-200 mg/day
Number of subjects: 1957

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1957

Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV)
Number of subjects: 1957
Study: 29623812

Group type: EXPERIMENTAL
Intervention: Ankle Mimicking Prosthetic Foot 4.0
Number of subjects: 18

Group type: COMPARATOR
Intervention: Current prosthesis
Number of subjects: 18
Study: 28835228

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 International Units cholecalciferol monthly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (arachidis oleum raffinatum)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melanoma subtype, site, and stage
Number of subjects: 0
Study: 25462419

Group type: EXPERIMENTAL
Intervention: Twice-daily HF-rTMS (10 Hz) over the left dorsolateral prefrontal cortex for 2 weeks (60,000 pulses)
Number of subjects: 27
Study: 23619819

Group type: EXPERIMENTAL
Intervention: 15 mg meloxicam tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: 15 mg meloxicam suspension
Number of subjects: 24
Study: 21073813

Group type: EXPERIMENTAL
Intervention: Intercept oral specimen collection device
Number of subjects: 21

Group type: COMPARATOR
Intervention: Statsure Saliva Sampler
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 21
Study: 18985552

Group type: EXPERIMENTAL
Intervention: Shoes incorporating an unstable sole (Masai Barefoot Technology), worn for a minimum of two hours per day for eight weeks.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Shoes incorporating an unstable sole (Masai Barefoot Technology)
Number of subjects: 10
Study: 20103575

Group type: EXPERIMENTAL
Intervention: Prehabilitation and early rehabilitation (28 patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (32 patients)
Number of subjects: 60
Study: 16275368

Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (100/50 microg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fluticasone alone (100 microg)
Number of subjects: 26
Study: 11459288

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted erythrocyte suspensions (LD-SAGM)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Non-leukocyte-depleted erythrocyte suspensions (SAGM)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 279
Study: 9587122

Group type: EXPERIMENTAL
Intervention: Prostate carcinoma tissue
Number of subjects: 26

Group type: COMPARATOR
Intervention: Benign hyperplasia tissue
Number of subjects: 26
Study: 7870725

Group type: EXPERIMENTAL
Intervention: Local applications of rifampicin and dimexide solutions
Number of subjects: 287

Group type: COMPARATOR
Intervention: BCG vaccine
Number of subjects: 287
Study: 3163523

Group type: EXPERIMENTAL
Intervention: 2.5% xylitol
Number of subjects: 11

Group type: COMPARATOR
Intervention: 2.5% sucrose
Number of subjects: 11

Group type: COMPARATOR
Intervention: water
Number of subjects: 11
Study: 31618132

Group type: EXPERIMENTAL
Intervention: Whole-breast radiotherapy (RT) after breast-conserving surgery (BCS)
Number of subjects: 748

Group type: COMPARATOR
Intervention: No radiotherapy (RT) after breast-conserving surgery (BCS)
Number of subjects: 748
Study: 29848993

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (SB) loading regimen (up to 100 mg∙kg‐1 for 10 days)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 26965540

Group type: EXPERIMENTAL
Intervention: Clinical variables present at the time of MI (including EF at presentation, length of stay, prior MI, lateral wall motion abnormality, peak troponin)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Clinical variables present at the time of MI (including EF at presentation, peak troponin, prior MI, presentation with ventricular fibrillation or cardiac arrest)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 231
Study: 24242334

Group type: EXPERIMENTAL
Intervention: Intravaginal progesterone implant between days 3 and 7 following fixed-time artificial insemination (FTAI)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2
Study: 22750958

Group type: EXPERIMENTAL
Intervention: Modified CIMT
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 28
Study: 19157346

Group type: EXPERIMENTAL
Intervention: Tropisetron plus subhypnotic propofol infusion
Number of subjects: 140

Group type: COMPARATOR
Intervention: Tropisetron alone
Number of subjects: 140
Study: 17978121

Group type: EXPERIMENTAL
Intervention: Initial training workshop on shoulder dystocia management (40 minutes)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Additional training for those who could not deliver after initial training
Number of subjects: 122
Study: 15034285

Group type: EXPERIMENTAL
Intervention: Low-dose omeprazole (L-OMP: 10 mg, q.d.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard-dose ranitidine (S-H2RA: 150 mg, b.i.d.)
Number of subjects: 100
Study: 11479461

Group type: EXPERIMENTAL
Intervention: Vasoflux (1, 4, 8, or 16 mg/kg as a bolus followed by 1, 4, 8, or 16 mg/kg per hour infusion)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Vasoflux (8 or 16 mg/kg)
Number of subjects: 277
Study: 9517745

Group type: EXPERIMENTAL
Intervention: Superior mesenteric artery clamp
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonclamp
Number of subjects: 40
Study: 11271221

Group type: EXPERIMENTAL
Intervention: Sandimmun Neoral (NOF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sandimmun (SIM)
Number of subjects: 0
Study: 3126339

Group type: EXPERIMENTAL
Intervention: rt-PA (70 mg with an initial bolus of 10 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Urokinase (3 million U with an initial bolus of 1.5 million U)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both rt-PA and Urokinase
Number of subjects: 125
Study: 29072931

Group type: EXPERIMENTAL
Intervention: Tuina treatment
Number of subjects: 92
Study: 26962636

Group type: EXPERIMENTAL
Intervention: External radiofrequency (RF) device combining RF heat, suction coupled vacuum, and oscillating electrical pulses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: External radiofrequency (RF) device
Number of subjects: 20
Study: 24968970

Group type: EXPERIMENTAL
Intervention: GTx‐758 1000 mg/d
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: GTx‐758 2000 mg/d
Number of subjects: 159

Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: GTx‐758
Number of subjects: 159
Study: 24002501

Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg per day)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 20391062

Group type: EXPERIMENTAL
Intervention: Couple-based HIV/STI risk-reduction intervention (CHSR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Attentional control wellness promotion (WP)
Number of subjects: 80